Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age. [PDF]
Rostad CA +11 more
europepmc +1 more source
Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study. [PDF]
Vicic N +9 more
europepmc +1 more source
Population-based cohort study assessing the effectiveness of maternal BNT162b2/mRNA-1273 vaccination against infant coronavirus disease 2019 outcomes during Omicron predominance: The VENUS study. [PDF]
Ishiguro C +4 more
europepmc +1 more source
Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera. [PDF]
Hickey TE +8 more
europepmc +1 more source
Immunostimulatory/Immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selection. [PDF]
Ivaturi V +10 more
europepmc +1 more source
A genome-wide association study identifies new loci associated with response to SARS-CoV-2 mRNA-1273 vaccine in a cohort of healthy healthcare workers. [PDF]
Cabrera-Serrano AJ +12 more
europepmc +1 more source
mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients. [PDF]
Girard B +10 more
europepmc +1 more source
Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children. [PDF]
Aglipay M +7 more
europepmc +1 more source
Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination [PDF]
Salma Younes +14 more
openalex +1 more source

